PSE Releases Major gPROMS FormulatedProducts Update

Extensive new reaction, model validation capabilities

LONDON–(BUSINESS WIRE)–#ADDoPT–Process Systems Enterprise (PSE), the Advanced Process Modelling
company, today released version 1.1 of its new gPROMS
FormulatedProducts® modelling platform for the integrated digital design
of robust formulated products and their manufacturing processes.

Developed in close collaboration with leading pharmaceutical,
agrochemical, consumer products and food organisations, gPROMS
FormulatedProducts deploys a mechanistic modelling approach to enable
scientists and engineers to screen formulations with complex phase
structures for quality attributes, determine whether they can be
manufactured robustly, and comprehensively explore the design space for
the whole formulation and manufacturing chain.

Sean Bermingham, head of PSE Formulated Products says, “We are moving
ahead rapidly with new developments under the guidance of PSE’s
Formulated Products Advisory Board as well as the input from the
Systems-based Pharmaceutics Alliance and our industrial and academic
partners in major R&D collaborations such as ADDoPT, REMEDIES, CMAC and
RCPE.”

Version 1.1 adds significant new functionality to the original release
with a wide range of enhanced new reactor and filtration libraries for
active pharmaceutical ingredient (API) manufacture. The release also
added libraries for fluid bed granulation, drum coating of tablets and
several sensors. All-new model validation workflows streamline the
capabilities for parameter estimation, allowing quicker and better
comparison of model predictions and experimental data, both for
experiments used to estimate mechanistic model parameters and for
additional experiments.

“Through Advisory Board guidance and PSE’s development expertise, gPROMS
FormulatedProducts uniquely meets the needs of the pharmaceutical,
agrochemical, consumer products and food organisations when it comes to
accelerating innovation, improving product and manufacturing process
robustness, and reducing time-to-market,” says Bermingham.

Built on PSE’s state-of-the art gPROMS® modelling platform,
gPROMS FormulatedProducts helps pharmaceutical companies optimise the
formulation and manufacture of drug substances and drug products using
mechanistic models of material, unit operations, as well as detailed
analysis of in-vivo drug product performance. It also provides
state-of-the-art capabilities to the agrochemical, consumer products and
food industries to enable model-based design and optimisation of
individual process operations such as reaction, crystallization, wet and
dry milling, spray drying, wet and dry granulation, blending and
tabletting, as well as product performance.

Contacts

Process Systems Enterprise
Kristen Hunter, +44-20-8563-0888
[email protected]
Editors:
www.psenterprise.com/news/pr180115